Exit Text Mode

Macular Disease Foundation Australia logo

    MDFA News

    New Nutrition Guidelines for AMD

    Latest research supports Mediterranean and Asian-style eating plans to reduce risk of AMD

    Read more
    Back
    All
    • All
    • AMD
    • Diabetic eye disease
    • Other macular conditions
    All
    • All
    • Advocacy / representation
    • Carers
    • Early detection and treatment
    • Eye health professional CPD
    • Macula Matters
    • MDFA work
    • Medicare Benefits Schedule review
    • National Disability Insurance Scheme
    • Nutrition
    • Real life stories
    • Research
    • Support services
    • Vision loss
    All
    • All
    • Article
    • Audio
    • Media release
    • Podcast
    • Video

    Most recent

    Government defers MBS private health insurance reclassification

    Macular Disease Foundation Australia (MDFA) has welcomed the Federal Government’s decision to defer the private health insurance reclassification of intravitreal (eye) injections from 1 July 2025 to 1 July 2026 and undertake further consultation.

    Call to Federal Government to bulk bill eye injections for pensioners

    We have released new research in collaboration with the University of New South Wales which has revealed the median total cost for people living with macular disease, who also receive sight-saving eye injections, is 12 percent* ($3,621) of the annual government pension payment.

    Opinion Editorial: Sight preservation should be a national priority

    By The Hon. Jillian Skinner, AM, former NSW Minister for Health.This article was originally published by News Corp.

    Living with macular disease consumes 12% of age pension payments

    Macular Disease Foundation Australia calls on the next Federal Government to bulk-bill sight-saving eye injections for pensioners; with the potential for creating a $140 million cost-saving per year.

    New treatment for Geographic Atrophy

    The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE® (pegcetacoplan) is welcome news, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease.

    Read our latest newsletter today

    Welcome to our final Vision Voice newsletter for the year.

    Survey shows new Eye Connect service benefiting AMD community 

    MDFA has received a positive response from the people participating in our new Eye Connect support service.

    MDFA showcases groundbreaking research projects in new impact report

    Macular Disease Foundation Australia (MDFA) has launched its new Research Impact Report, which showcases the groundbreaking projects our organisation has funded to help reduce the impact of macular disease.

    Macular Disease Foundation Australia responds to the Australian Government’s planned MBS change

    The Federal Government has announced that from 1 July 2025, people receiving sight-saving eye (intravitreal) injections to treat macular disease will no longer receive health fund benefits for this treatment if it is performed in private hospitals and day surgeries.

    Loading...
    Loading...